2 results
Approved WMOWill not start
Our aim is to assess the sequential response of different endothelial markers following DDAVP administration. This information will be used to expand the population PK model and may enhance our insight in the mechanisms underlying the DDAVP response…
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…